168 related articles for article (PubMed ID: 23720456)
1. Development of a novel long-acting antidiabetic FGF21 mimetic by targeted conjugation to a scaffold antibody.
Huang J; Ishino T; Chen G; Rolzin P; Osothprarop TF; Retting K; Li L; Jin P; Matin MJ; Huyghe B; Talukdar S; Bradshaw CW; Palanki M; Violand BN; Woodnutt G; Lappe RW; Ogilvie K; Levin N
J Pharmacol Exp Ther; 2013 Aug; 346(2):270-80. PubMed ID: 23720456
[TBL] [Abstract][Full Text] [Related]
2. Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models--association with liver and adipose tissue effects.
Xu J; Stanislaus S; Chinookoswong N; Lau YY; Hager T; Patel J; Ge H; Weiszmann J; Lu SC; Graham M; Busby J; Hecht R; Li YS; Li Y; Lindberg R; Véniant MM
Am J Physiol Endocrinol Metab; 2009 Nov; 297(5):E1105-14. PubMed ID: 19706786
[TBL] [Abstract][Full Text] [Related]
3. Mechanistic investigation of the preclinical pharmacokinetics and interspecies scaling of PF-05231023, a fibroblast growth factor 21-antibody protein conjugate.
Giragossian C; Vage C; Li J; Pelletier K; Piché-Nicholas N; Rajadhyaksha M; Liras J; Logan A; Calle RA; Weng Y
Drug Metab Dispos; 2015 Jun; 43(6):803-11. PubMed ID: 25805881
[TBL] [Abstract][Full Text] [Related]
4. FGF21 analogs of sustained action enabled by orthogonal biosynthesis demonstrate enhanced antidiabetic pharmacology in rodents.
Mu J; Pinkstaff J; Li Z; Skidmore L; Li N; Myler H; Dallas-Yang Q; Putnam AM; Yao J; Bussell S; Wu M; Norman TC; Rodriguez CG; Kimmel B; Metzger JM; Manibusan A; Lee D; Zaller DM; Zhang BB; DiMarchi RD; Berger JP; Axelrod DW
Diabetes; 2012 Feb; 61(2):505-12. PubMed ID: 22210323
[TBL] [Abstract][Full Text] [Related]
5. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.
Green BD; Lavery KS; Irwin N; O'harte FP; Harriott P; Greer B; Bailey CJ; Flatt PR
J Pharmacol Exp Ther; 2006 Aug; 318(2):914-21. PubMed ID: 16648370
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics (PK), pharmacodynamics (PD) and integrated PK/PD modeling of a novel long acting FGF21 clinical candidate PF-05231023 in diet-induced obese and leptin-deficient obese mice.
Weng Y; Chabot JR; Bernardo B; Yan Q; Zhu Y; Brenner MB; Vage C; Logan A; Calle R; Talukdar S
PLoS One; 2015; 10(3):e0119104. PubMed ID: 25790234
[TBL] [Abstract][Full Text] [Related]
7. Long-acting FGF21 has enhanced efficacy in diet-induced obese mice and in obese rhesus monkeys.
Véniant MM; Komorowski R; Chen P; Stanislaus S; Winters K; Hager T; Zhou L; Wada R; Hecht R; Xu J
Endocrinology; 2012 Sep; 153(9):4192-203. PubMed ID: 22798348
[TBL] [Abstract][Full Text] [Related]
8. A Novel Fc-FGF21 With Improved Resistance to Proteolysis, Increased Affinity Toward β-Klotho, and Enhanced Efficacy in Mice and Cynomolgus Monkeys.
Stanislaus S; Hecht R; Yie J; Hager T; Hall M; Spahr C; Wang W; Weiszmann J; Li Y; Deng L; Winters D; Smith S; Zhou L; Li Y; Véniant MM; Xu J
Endocrinology; 2017 May; 158(5):1314-1327. PubMed ID: 28324011
[TBL] [Abstract][Full Text] [Related]
9. Treating diabetes and obesity with an FGF21-mimetic antibody activating the βKlotho/FGFR1c receptor complex.
Foltz IN; Hu S; King C; Wu X; Yang C; Wang W; Weiszmann J; Stevens J; Chen JS; Nuanmanee N; Gupte J; Komorowski R; Sekirov L; Hager T; Arora T; Ge H; Baribault H; Wang F; Sheng J; Karow M; Wang M; Luo Y; McKeehan W; Wang Z; Véniant MM; Li Y
Sci Transl Med; 2012 Nov; 4(162):162ra153. PubMed ID: 23197570
[TBL] [Abstract][Full Text] [Related]
10. Molecular hydrogen improves obesity and diabetes by inducing hepatic FGF21 and stimulating energy metabolism in db/db mice.
Kamimura N; Nishimaki K; Ohsawa I; Ohta S
Obesity (Silver Spring); 2011 Jul; 19(7):1396-403. PubMed ID: 21293445
[TBL] [Abstract][Full Text] [Related]
11. A solid-phase PEGylation strategy for protein therapeutics using a potent FGF21 analog.
Song L; Zhu Y; Wang H; Belov AA; Niu J; Shi L; Xie Y; Ye C; Li X; Huang Z
Biomaterials; 2014 Jun; 35(19):5206-15. PubMed ID: 24685265
[TBL] [Abstract][Full Text] [Related]
12. [Expression and pharmacological evaluation of fusion protein FGF21-L-Fc].
Yao WB; Ren GP; Han Y; Cao HW; Gao HM; Kan FM; Wang Q; Li DS
Yao Xue Xue Bao; 2011 Jul; 46(7):787-92. PubMed ID: 22010347
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the antidiabetic effects of brain-derived neurotrophic factor and thiazolidinediones in obese diabetic mice.
Yamanaka M; Itakura Y; Tsuchida A; Nakagawa T; Noguchi H; Taiji M
Diabetes Obes Metab; 2007 Nov; 9(6):879-88. PubMed ID: 17924870
[TBL] [Abstract][Full Text] [Related]
14. Fusion of fibroblast growth factor 21 to a thermally responsive biopolymer forms an injectable depot with sustained anti-diabetic action.
Gilroy CA; Roberts S; Chilkoti A
J Control Release; 2018 May; 277():154-164. PubMed ID: 29551712
[TBL] [Abstract][Full Text] [Related]
15. Rationale-Based Engineering of a Potent Long-Acting FGF21 Analog for the Treatment of Type 2 Diabetes.
Hecht R; Li YS; Sun J; Belouski E; Hall M; Hager T; Yie J; Wang W; Winters D; Smith S; Spahr C; Tam LT; Shen Z; Stanislaus S; Chinookoswong N; Lau Y; Sickmier A; Michaels ML; Boone T; Véniant MM; Xu J
PLoS One; 2012; 7(11):e49345. PubMed ID: 23209571
[TBL] [Abstract][Full Text] [Related]
16. Fibroblast Growth Factor 21 As an Emerging Therapeutic Target for Type 2 Diabetes Mellitus.
So WY; Leung PS
Med Res Rev; 2016 Jul; 36(4):672-704. PubMed ID: 27031294
[TBL] [Abstract][Full Text] [Related]
17. A better anti-diabetic recombinant human fibroblast growth factor 21 (rhFGF21) modified with polyethylene glycol.
Huang Z; Wang H; Lu M; Sun C; Wu X; Tan Y; Ye C; Zhu G; Wang X; Cai L; Li X
PLoS One; 2011; 6(6):e20669. PubMed ID: 21673953
[TBL] [Abstract][Full Text] [Related]
18. Polyethylene glycol modified FGF21 engineered to maximize potency and minimize vacuole formation.
Xu J; Bussiere J; Yie J; Sickmier A; An P; Belouski E; Stanislaus S; Walker KW
Bioconjug Chem; 2013 Jun; 24(6):915-25. PubMed ID: 23594041
[TBL] [Abstract][Full Text] [Related]
19. Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways.
Wente W; Efanov AM; Brenner M; Kharitonenkov A; Köster A; Sandusky GE; Sewing S; Treinies I; Zitzer H; Gromada J
Diabetes; 2006 Sep; 55(9):2470-8. PubMed ID: 16936195
[TBL] [Abstract][Full Text] [Related]
20. A novel long acting DPP-IV inhibitor PKF-275-055 stimulates β-cell proliferation resulting in improved glucose homeostasis in diabetic rats.
Akarte AS; Srinivasan BP; Gandhi S
Biochem Pharmacol; 2012 Jan; 83(2):241-52. PubMed ID: 22015634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
